Quentis Therapeutics Overview
- Founded
- 2016

- Status
- Private
- Employees
- 16

- Latest Deal Type
- Grant
- Latest Deal Amount
- $1M

- Investors
- 10
Quentis Therapeutics General Information
Description
Developer of immuno-therapeutics designed to translate novel biology into new therapeutic approaches. The company's therapeutics are designed to target endoplasmic reticulum (ER) stress pathways and awaken the immune system's ability to fight the tumor, enabling patients to boost anti-tumor immunity in cancer
Contact Information
- 430 East 29th Street
- Suite 1005
- New York, NY 10016
- United States
Quentis Therapeutics Timeline
Quentis Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Grant | 03-Dec-2018 | $1M | 000.00 | Completed | Product Development | |
4. Accelerator/Incubator | 01-Sep-2018 | 000.00 | Completed | Product Development | ||
3. Early Stage VC (Series A) | 27-Feb-2018 | 000.00 | 000.00 | 000.00 | Completed | Product Development |
2. Seed Round | 22-Nov-2017 | $2M | $5M | 0000 | Completed | Startup |
1. Seed Round | 09-Jun-2016 | $3M | $3M | 000 | Completed | Startup |
Quentis Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Seed | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
Quentis Therapeutics Comparisons
Industry
00000000
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialQuentis Therapeutics Competitors (43)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
ImmunityBio | Venture Capital-Backed | Culver City, CA | 000 | 00000 | 000000000000 | 00000 |
000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
000000 | Venture Capital-Backed | Lebanon, NH | 000 | 00000 | 0000000000 0 | 00000 |
0000 | Formerly VC-backed | Emeryville, CA | 00 | 00000 | 00000000 | 00000 |
000000000 00000000 | Venture Capital-Backed | Salt Lake City, UT | 000 | 00000 | 00000000000 | 00000 |
Quentis Therapeutics Executive Team (7)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
David Feldman | Director, Finance & Operations | ||
Joseph Vacca Ph.D | Head of Chemistry | ||
Laurie Glimcher MD | Scientific Co-Founder & Chairman of Scientific Advisory Board |
Quentis Therapeutics Board Members (7)
Name | Representing | Role | Since |
---|---|---|---|
Amy Schulman JD | Polaris Partners | Board Member | 000 0000 |
Carlo Rizzuto Ph.D | Versant Venture | Board Member | 000 0000 |
Laurie Glimcher MD | Self | Scientific Co-Founder & Chairman of Scientific Advisory Board | 000 0000 |
Mark Murcko Ph.D | Self | Board Member | 000 0000 |
Michael Foley Ph.D | Quentis Therapeutics | Board Member | 000 0000 |
Quentis Therapeutics Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialQuentis Therapeutics Investors (10)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
New York City Economic Development | Government | 000 0000 | 000000 0 | ||
JLABS | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
AbbVie Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
New York Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |